A Phase 4 interventional study of Tracleer® in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 17 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-09-22.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 9th largest by enrollment, is one of 2 that started in 2004, is one of 5 in phase 4, and was the 7th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 8 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 37 across the 18 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 9 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 38th largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2004, is one of 11 in phase 4, and was the 10th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.
This is a multicenter, open-label, single -arm study with bosentan, initial dose of 62.5 mg b.i.d., with a target dose of 125 mg b.i.d. All patients will be assessed for eligibility during the baseline visit (same as Week 16, end of study BREATHE-5 visit), and will have the option to enter into the open-label extension study at a starting dose of 62.5 mg b.i.d., for safety reasons. Visit 2 is required as a safety visit to assess oxygen saturation (SpO2) after 1 week of bosentan treatment. Patients will return for Visit 4 after 4 weeks of treatment, and the dose will be up-titrated to 125 mg b.i.d. or maintained at 62.5 mg b.i.d. at the judgement of the investigator. Data will be collected for a total of 24 weeks or until the sponsor decides to stop the study. If the results from Study AC-052-403 or AC-052-405 demonstrate significant safety issues, this extension study may be terminated at the sponsor's request.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
Drug: Tracleer®
Patients will receive up to 125 mg b.i.d. of Tracleer.
Change in 6-minute Walk Distance
Time frame: from baseline to week 24
Change in Borg Dyspnea Index
Borg scale a numerical scale for assessing dyspnea, from 0 representing no dyspnea to 10 as maximal dyspnea.
Time frame: from baseline to week 24
Number of Participants With a Change in WHO Functional Class
Number of participants with a change in WHO functional class from baseline to week 24. A change from a higher to a lower functional class (i.e. III to II, III to I or II to I) is considered as an improvement.
Time frame: from baseline to week 24
Eight centers in six countries: Germany (1), Italy (2), the Netherlands (1), Spain (1), U.K. (2), U.S.A. (1) Patients with stable PAH upon completion of the BREATHE-5 randomized, double-blind, placebocontrolled 16-week study were given option to enter into the open-label extension study.
| Milestone | Tracleer |
|---|---|
| Started | 37 |
| Completed | 35 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| m | Overall Study Arm |
|---|---|
| Change in 6-minute Walk Distance | 13.5 ± 57.2 |
Borg scale a numerical scale for assessing dyspnea, from 0 representing no dyspnea to 10 as maximal dyspnea.
| units on a scale | Overall Study Arm |
|---|---|
| Change in Borg Dyspnea Index | 0.1 ± 1.4 |
Number of participants with a change in WHO functional class from baseline to week 24. A change from a higher to a lower functional class (i.e. III to II, III to I or II to I) is considered as an improvement.
| participants | Overall Study Arm |
|---|---|
| Number of Participants With a Change in WHO Functional Class | 13 |
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tracleer | — | 7/37 (18.9%) | 25/37 (67.6%) |
| Event | Tracleer |
|---|---|
| ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions | 2/37 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/37 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 1/37 |
| GASTROENTERITIS VIRALInfections and infestations | 1/37 |
| LETHARGYNervous system disorders | 1/37 |
| NAUSEAGastrointestinal disorders | 1/37 |
| PALPITATIONSCardiac disorders | 1/37 |
| pregnancyPregnancy, puerperium and perinatal conditions | 1/37 |
| sudden deathGeneral disorders | 1/37 |
| rectal hemorrhageGastrointestinal disorders | 1/37 |
| Event | Tracleer |
|---|---|
| OEDEMA PERIPHERALGeneral disorders | 7/37 |
| NASOPHARYNGITISInfections and infestations | 5/37 |
| CHEST PAINGeneral disorders | 4/37 |
| DIARRHOEAGastrointestinal disorders | 3/37 |
| FATIGUEGeneral disorders | 2/37 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/37 |
| VIRAL INFECTIONInfections and infestations | 2/37 |
| NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders | 2/37 |
| PALPITATIONSCardiac disorders | 2/37 |
| DIZZINESSNervous system disorders | 2/37 |
| Age, Continuous(Years) | Overall Study Arm |
|---|---|
| Mean | 39.8 ± 11.8 |
| Sex: Female, Male(Participants) | Overall Study Arm |
|---|---|
| Female | 25 |
| Male | 12 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jan 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 10 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Pulmonary Arterial Hypertension →